RESEARCH ARTICLE

Risk factors for disease progression in COVID-19 patients

Min Cheol Chang¹, Yu-Kyung Park², Bong-Ok Kim³ and Donghwi Park⁴*

Abstract

Background: Coronavirus disease (COVID-19) is rapidly spreading worldwide. Although 10–20% of patients with COVID-19 have severe symptoms, little is known about the risk factors related to the aggravation of COVID-19 symptoms from asymptomatic or mild to severe disease states.

Methods: This retrospective study included 211 patients who were asymptomatic or with mild presentations of COVID-19. We evaluated the differences in demographic and clinical data between the cured (discharged to home) and transferred (aggravated to severe-stage COVID-19) groups.

Results: A multivariate logistic analysis showed that body temperature, chills, initial chest X-ray findings, and the presence of diabetes were significantly associated with predicting the progression to severe stage of COVID-19 (p < 0.05). The odds ratio of transfer in patients with COVID-19 increased by 12.7-fold for abnormal findings such as haziness or consolidation in initial chest X-ray, 6.32-fold for initial symptom of chills, and 64.1-fold for diabetes.

Conclusions: Even if patients are asymptomatic or have mild symptoms, clinicians should closely observe patients with COVID-19 presenting with chills, body temperature > 37.5 °C, findings of pneumonia in chest X-ray, or diabetes.

Keywords: Coronavirus disease, Risk factor: symptom aggravation, Chilling, Fever, Diabetes

Background

After the first case of coronavirus disease (COVID-19) in Wuhan, China in late December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to over 200 countries in about 3 months. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a pandemic [1–3]. The estimated case-fatality rate for 2019-nCoV is around 3.5%, which is similar to that of Spanish influenza (2–3%) and much higher than that of seasonal influenza (0.1%) [4]. Over 80% of COVID-19 cases have mild symptoms; however, 10–20% of COVID-19 cases proceed to a severe stage [5]. The identification of factors associated with the aggravation of patient symptoms from asymptomatic-mild to severe is essential for providing efficient and appropriate management to patients with COVID-19.

Most studies to date have investigated risk factors of mortality in patients with COVID-19 [6–8]. Older age and history of coronary vascular disease were reported to increase the risk of death from COVID-19 [6–8]. However, little is known about the risk factors related to the aggravation of COVID-19 symptoms from asymptomatic or mild to severe disease states.

The current study recruited patients with COVID-19 who presented no or mild symptoms from a single center in South Korea and evaluated factors aggravating their symptoms to severe-stage disease.

* Correspondence: bdome@hanmail.net

¹Department of Physical Medicine and Rehabilitation, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojin sunhwando-ro, Ulsan 44033, Dong-gu, Republic of Korea

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Methods

Study design and participants
This retrospective cohort study investigated adult inpatients (≥18 years) from Korea Worker’s Compensation & Welfare Service Daegu Hospital (Daegu, South Korea). We screened all adult patients diagnosed with COVID-19 according to WHO interim guidance and who were discharged by cure or transferred to specialized infectious disease hospitals due to aggravated symptoms between Feb 28, 2020 (i.e., when the first patients were admitted) and March 31, 2020.

The study hospital was originally a public rehabilitation hospital. However, after the large spread of COVID-19 across Daegu city, the government assigned the hospital as a public infectious disease hospital for isolating and managing asymptomatic or mild COVID-19 patients in Daegu. Patients with COVID-19 were classified into four levels (asymptomatic, mild, moderate, and severe) according to the severity of their symptoms (Table 1). The four-classification system was made by Daegu Medical Association for fast classification of patients with COVID-19. Patients with COVID-19 admitted to the study hospital who progressed to severe-stage disease were transferred to specialized infectious disease hospitals. Therefore, we enrolled many patients who were hospitalized for asymptomatic or mild COVID-19. We divided these patients into cured and transferred groups according to their treatment results. The cured group included initially asymptomatic or mildly symptomatic COVID-19 patients who were discharged to home after complete cure. The transferred group included COVID-19 patients with initial asymptomatic or mild stage who were transferred to a specialized infectious disease hospital due to COVID-19 progression to severe stage. This study was approved by the Institutional Review Board of Yeungnam University Hospital and the requirement for informed consent was waived by the Ethics Commission.

COVID-19 treatments
All hospitalized patients were administered antibiotics and antiviral treatment. The antibiotics included azithromycin 500 mg (Azirormax®) and cefixime 200 mg (Pocef®) peroral. The antiviral treatments were either lopinavir/ritonavir 200 mg/50 mg (Kalitra®) two tablets and hydroxychloroquine sulfate 400 mg (Oxiklorine®) peroral.

Data collection
We extracted clinical, epidemiological, demographic, medication, and outcome data from patient electronic medical records. Two physicians (M.C. and D.P.) independently investigated all data using a standardized data collection form.

Laboratory procedures
The diagnosis of COVID-19 was performed using a real-time polymerase chain reaction (RT-PCR) kit approved by the Korean Centers for Disease Control and Prevention (KCDC) and Korean Ministry of Food and Drug Safety [9].

Risk factors
We investigated the chronic medical underlying diseases of the patients, including diabetes, chronic kidney disease (CKD), chronic liver disease, chronic lung disease, chronic cardiovascular disease, carcinoma, dyslipidemia, and hypertension, according to the National Health Insurance System of South Korea diagnosis codes and based on the results of previous studies on the risk factors for COVID-19 and classification system announced by the KCDC. Chronic lung disease was defined as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), or bronchiectasis. We also investigated the presence of allergic rhinitis in patients with COVID-19 and assessed the initial symptoms and vital signs, such as cough, sputum, myalgia, chills, rhinorrhea, dyspnea, chest pain, body temperature, and oxygen saturation in pulse oximetry.

Statistical analysis
We performed independent t- and chi-square tests to assess differences in demographic and clinical data between the cured and transferred groups. Moreover, we also used multivariate logistic analysis through the forward selection method to analyze the correlations between clinical parameters (underlying diseases, initial symptoms, and initial vital signs) and progression to severe disease stage in patients with COVID-19. Finally, we performed a receiver operating characteristic (ROC) analysis in each group to evaluate the accuracy of predictive factors for body temperature for the progression to moderate-stage disease in patients with COVID-19. All statistical analyses were conducted using IBM SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk, NY, USA).

Table 1 Classification of patients with COVID-19 according to symptom severity

| Classification | Classification criteria |
|----------------|-------------------------|
| Asymptomatic   | Asymptomatic or body temperature < 37.5°C |
| Mild           | Body temperature ≥ 37.5°C but O₂ supply not required |
| Moderate       | O₂ supply via nasal or venturi mask required |
| Severe         | High-flow O₂ supply or mechanical ventilation required |
Results

Demographics and clinical characteristics of patients with COVID-19

The final analysis in this study included 211 adult patients hospitalized at Korea Worker’s Compensation & Welfare Service Daegu Hospital with COVID-19 before March 31, 2020. Thirteen patients transferred to a specialized infectious disease hospital with negative pressure rooms during hospitalization and 198 patients were discharged to home. The median age of the 211 patients was 37.55 ± 14.53 years (range: 18 to 74 years) and the sex ratio was 74:137 (male:female). Comorbidities were present in 33 patients (15.6%), with hypertension (13 patients, 6.2%) the most common, followed by allergic rhinitis (nine patients, 4.3%) and dyslipidemia (six patients, 2.8%) (Table 2).

Risk factors for progression to moderate-stage COVID-19

Comparison of demographic and clinical data between the cured (discharged to home) and transferred (to specialized infectious disease hospital) groups showed a significant difference in age (p-value < 0.05) (Table 2). Comparison of the initial vital signs and symptoms between the cured and transferred groups showed significant differences in body temperature, initial chest x-ray findings, chills, myalgia, and dyspnea (p < 0.05) (Table 2).

Comparison of the underlying comorbidities between the cured and transferred groups showed significantly higher presence of hypertension, diabetes, and dyslipidemia in the transferred group than in the cured group (p < 0.05) (Table 2). The presence of cancer, chronic lung disease, cardiovascular disease, and allergic rhinitis

Table 2 Clinical characteristics of patients with COVID-19 on admission

| Variable                                | Total, n (%) | Cured Group, n (%) | Transferred Group, n (%) | P-value |
|-----------------------------------------|--------------|--------------------|--------------------------|---------|
| Total, n (%)                            | 211 (100%)   | 198 (93.8%)        | 13 (6.2%)                |         |
| Age, years                              | 37.55 ± 14.53| 36.47 ± 14.04      | 54.08 ± 11.98            | .000*   |
| Sex, n (%)                              |              |                    |                          |         |
| Female                                  | 137 (64.9%)  | 129 (65.2%)        | 8 (61.5%)                | .791    |
| Male                                    | 74 (35.1%)   | 69 (34.8%)         | 5 (38.5%)                |         |
| Initial vital sign & symptoms           |              |                    |                          |         |
| Body temperature (°C)                   | 37.09 ± 4.85 | 37.04 ± 0.42       | 37.81 ± 0.76             | .003*   |
| Oxygen saturation (%)                   | 97.20 ± 11.88| 97.24 ± 11.93      | 96.57 ± 9.76             | .096    |
| Chills                                  | 22 (10.4%)   | 16 (8.1%)          | 6 (46.2%)                | .000*   |
| Cough                                   | 92 (43.6%)   | 83 (41.9%)         | 9 (69.2%)                | .054    |
| Myalgia                                 | 44 (20.9%)   | 35 (17.7%)         | 9 (69.2%)                | .000*   |
| Sputum                                  | 66 (31.3%)   | 59 (29.8%)         | 7 (53.8%)                | .070    |
| Rhinorrhea                              | 58 (27.5%)   | 52 (26.3%)         | 6 (46.2%)                | .120    |
| Sore throat                             | 46 (21.8%)   | 43 (21.7%)         | 3 (23.1%)                | .908    |
| Headache                                | 53 (25.1%)   | 47 (23.7%)         | 6 (46.2%)                | .071    |
| Diarrhea                                | 33 (15.6%)   | 30 (15.6%)         | 3 (23.1%)                | .446    |
| Dyspnea                                 | 26 (12.3%)   | 21 (10.6%)         | 5 (38.5%)                | .003*   |
| Chest pain                              | 24 (11.4%)   | 22 (11.1%)         | 2 (15.4%)                | .643    |
| Findings of pneumonia in chest X-ray    | 54 (25.6%)   | 43 (21.7%)         | 11 (84.6%)               | .000*   |
| Comorbidities                           |              |                    |                          |         |
| Hypertension                            | 13 (6.2%)    | 9 (4.5%)           | 4 (30.8%)                | .000*   |
| Diabetes                                | 4 (1.9%)     | 1 (0.5%)           | 3 (23.1%)                | .000*   |
| Chronic kidney disease                  | 0 (0%)       | 0 (0%)             | 0 (0%)                   | .999    |
| Dyslipidemia                            | 6 (2.8%)     | 4 (2.0%)           | 2 (15.4%)                | .005*   |
| Chronic lung disease                    | 6 (2.8%)     | 6 (3%)             | 0 (0%)                   | .524    |
| Allergic rhinitis                       | 9 (4.3%)     | 9 (4.5%)           | 0 (0%)                   | .432    |
| Carcinoma                               | 1 (0.5%)     | 1 (0.5%)           | 0 (0%)                   | .797    |
| Cardiovascular disease                  | 2 (0.9%)     | 2 (1.0%)           | 0 (0%)                   | .716    |

*p-values were calculated by independent T- or chi-square tests, as appropriate. *Significant difference between groups (p < 0.05). COVID-19: coronavirus disease 2019. Values: mean ± standard deviation
did not differ significantly between the cured and transferred groups.

Multivariate logistic analysis showed that body temperature, chills, initial chest x-ray findings, and the presence of diabetes were significant parameters predicting the progression to severe-stage COVID-19 ($p < 0.05$) (Table 3). The odd ratios of transferred patients with COVID-19 increased by 12.7-fold for abnormal findings such as haziness or consolidation in initial chest x-ray, 6.32-fold for initial chills, and 64.1-fold for diabetes (Table 4).

In patients with COVID-19, the area under the ROC curve of body temperature for predicting progression to severe-stage COVID-19 was 0.742 (95% CI, 0.646–0.936; $p < 0.001$) (Table 4). The optimal cutoff value obtained from the maximum Youden index $J$ was 37.5°C (sensitivity: 61.5%, specificity: 90.4%) and the odds ratio of progression to severe-stage COVID-19 increased by 1.24-fold for every 0.1°C increase in body temperature (Fig. 1).

### Discussion

In this study, we found that chills, body temperature > 37.5°C, abnormal findings such as haziness or consolidation on initial chest X-ray, or diabetes were risk factors for aggravation of COVID-19 symptoms from asymptomatic-mild to severe.

Among patients with diabetes, the odds ratio for progression to severe-stage COVID-19 was about 60 times higher than that of COVID-19 patients without diabetes, which was the highest ratio among statistically significant aggravating factors in our study. The high risk of progression to severe-stage COVID-19 in patients with diabetes is likely because of hyperglycemic conditions that cause immune dysfunction including impaired neutrophil function, antioxidant system function, and humoral immunity [10–12]. Additionally, patients with diabetes are vulnerable to nosocomial infection, which can deteriorate their general condition and aggravate COVID-19 symptoms [13].

Other than diabetes, chills, body temperature > 37.5°C, and abnormal findings on initial chest X-ray such as haziness or consolidation were risk factors for proceeding to severe-stage disease. Chills and fever are responses to released inflammatory mediators such as cytokines and chemokines [14, 15]. These inflammatory mediators cause tissue damage and organ dysfunction by stimulating toxic oxygen derivatives [16–18]. Accordingly, chills and fever can be clinical signs indicating poor patient prognosis. Also, lung haziness or consolidation on chest X-ray indicated the significant effects of 2019-nCoV, suggesting the high possibility of progression to severe conditions in patients with these abnormal findings.

Previous studies reported age to be the most important predictor of death in patients with COVID-19 [6, 8]. In contrast, in our study, age was not a predictive factor for symptom aggravation in these patients. This inconsistency may be because the patients enrolled in our study were relatively young (average age: 37.6 years). Also, our primary outcome was not risk factors for mortality but rather factors for symptom aggravation. However, although the difference was not statistically significant, we observed a tendency for older patients (average age: 54.1 years) to progress to severe-stage disease compared to relatively younger patients (average age: 36.5 years). The age-dependent functional defects in immunologic cells lead to impaired suppression of viral replication [19–21].

In 2020, some studies evaluating the risk factors of mortality in patients with COVID-19 reported higher

| Parameter                               | Beta coefficient | Standard error | Multivariable OR (95% CI) | $p$-value |
|-----------------------------------------|------------------|----------------|---------------------------|------------|
| Age                                     | .060             | .046           | 1.061 (0.971–1.161)       | .192       |
| Body temperature                        | .216             | .070           | 1.241 (1.082–1.424)       | .002*      |
| Dyspnea                                 | 2.049            | 1.454          | 7.760 (6.449–134.131)     | .159       |
| Myalgia                                 | 1.654            | 1.082          | 5.227 (6.027–46.550)      | .126       |
| Chills                                  | 1.844            | .855           | 6.321 (1.183–33.772)      | .031*      |
| Findings of pneumonia in chest x-ray    | 2.541            | .98            | 12.690 (1.86–86.602)      | .010*      |
| Diabetes                                | 4.161            | 1.345          | 64.134 (4.593–895.479)    | .002*      |
| Hypertension                            | 1.091            | 1.866          | 2.976 (0.770–115.224)     | .559       |
| Dyslipidemia                            | .185             | 2.459          | 1.203 (0.010–148.987)     | .940       |

$p$-values were obtained by multivariate logistic analysis *Significant difference noted ($p < .05$)

## Table 4 ROC curve analysis of body temperature for progression to severe-stage COVID-19

| Parameter       | AUC   | Standard error | $p$-value | 95% CI  |
|-----------------|-------|----------------|-----------|---------|
| Body temperature| .742  | .052           | .000*     | 0.646–0.936 |

*Significant difference noted ($p < .05$)

ROC receiver operating characteristic, AUC area under the ROC curve, CI confidence interval
death rates with increasing age [8, 11]. Regarding underlying diseases, among 416 hospitalized patients with COVID-19 in Wuhan, China, [7, 6] Shi et al. observed a higher mortality rate in 82 patients with cardiac injury rate than that in 334 patients without cardiac injury [7]. However, to our knowledge, no other study has yet evaluated factors associated with the aggravation of COVID-19 symptoms. Therefore, our study is first to report factors aggravating COVID-19 symptoms.

**Conclusion**

In conclusion, we found that asymptomatic patients or patients with mild symptoms including chills, body temperature > 37.5 °C, findings of pneumonia on chest X-ray, or diabetes mellitus were prone to developing severe-stage COVID-19. Therefore, clinicians should consider these potential risk factors for symptom aggravation during management of COVID-19 patients. Our study has some limitations, including the relatively small number of patients, particularly those with increased symptom deterioration. Also, we recruited only patients with asymptomatic-mild-stage and not moderate or severe-stage disease. Therefore, further studies with larger patient numbers and patients with various stages of disease are warranted.

**Abbreviations**

COVID-19: Coronavirus disease; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; ILD: Interstitial lung disease; IPF: Idiopathic pulmonary fibrosis; ROC: Receiver operating characteristic; KCDC: Korean Centers for Disease Control and Prevention; WHO: World Health Organization

**Acknowledgements**

Not applicable.

**Authors’ contributions**

DP and MCC created the research data and wrote the draft of the manuscript. SI and KK determined phenotypic properties of isolates. BK and YP collected the clinical isolates. All authors read, made significant edits to the first version, and approved the final manuscript.

**Funding**

The present study was supported by a National Research Foundation of Korea grant funded by the Korean government (grant no. NRF-2019M3E5D1A02068106). They had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The study protocol was approved by the ethics committee of Yeungnam University Hospital. Individual informed consent was waived by the ethics committee listed above because this study used currently existing sample collected during the course of routine medical care and did not pose any additional risks to the patients. Informed consent about study participation was officially announced by mail and poster. All patient data were anonymized prior to the analysis.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Rehabilitative Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea. 2Department of Internal Medicine, Korea Worker’s Compensation & Welfare Service Daegu Hospital, Daegu, Republic of Korea. 3Department of Rehabilitation Medicine, College of Medicine, Yeungnam University Hospital, Daegu, Republic of Korea. 4Department of Rehabilitation Medicine, College of Medicine, Yeungnam University Hospital, Daegu, Republic of Korea. 5Department of Physical Medicine and Rehabilitation, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojin, sunhwando-ro, Ulsan 44033, Dong-gu, Republic of Korea.

**Received: 21 April 2020 Accepted: 10 June 2020**

**Published online: 23 June 2020**

**References**

1. Chang MC, Park D: How should rehabilitative departments of hospitals prepare for coronavirus disease 2019? Am J Phys Med Rehabil 2020.

2. Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, Eggo RM, Centre for Mathematical Modelling of infectious diseases C-wg: early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis 2020.

3. Chang MC, Seo WS, Park D, Hur J: Analysis of SARS-CoV-2 Screening Clinic (Including Drive-Through System) Data at a Single University Hospital in South Korea from 27 January 2020 to 31 March 2020 during the COVID-19 Outbreak. Healthcare (Basel). 2020;8(2).

4. Gates B: Responding to Covid-19 - a once-in-a-century pandemic? N Engl J Med 2020.

5. Wang Y, Wang Y, Chen Y, Qin Q: Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020.

6. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Countries. 2020(14)(2):125–8.
7. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, et al: Association of Cardiac Injury with Mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020.

8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

9. Chang MC, Hur J, Park D: Interpreting the COVID-19 test results: a guide for physiatrists. Am J Phys Med Rehabil 2020.

10. Ayelign B, Negash M, Genetu M, Wondmagegn T, Shibabaw T. Immunological impacts of diabetes on the susceptibility of mycobacterium tuberculosis. J Immunol Res. 2019;2019:6196532.

11. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Ind J Endocrinol Metab. 2012;16(Suppl 1):S27–36.

12. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26(3–4):259–65.

13. Vardakas KZ, Siempos II, Falagas ME. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabet Med. 2007;24(10):1168–71.

14. Chen H, Lin C, Fan Z, Yu W, Cao M, Ke C, Jao X. Serum cytokines and clinical features in patients with fever and thrombocytopenia syndrome. Clin Chim Acta. 2019;494:22–30.

15. Liu Y, Freed DC, Li L, Tang A, Li F, Murray EM, Adler SP, McVoy MA, Rupp RE, Barrett D, et al. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection. J Virol. 2019;93(23).

16. Korish AA, Arafa MM. Propolis derivatives inhibit the systemic inflammatory response and protect hepatic and neuronal cells in acute septic shock. Braz J Infect Dis. 2011;15(4):332–8.

17. Laskin DL, Pendino KJ. Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol. 1995;35:655–77.

18. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126–67.

19. Bektas A, Schurman SH, Sen R, Fernucci L. Human T cell immunosenescence and inflammation in aging. J Leukoc Biol. 2017;102(4):977–88.

20. Chung HY, Kim DH, Lee BK, Chung KW, Chung S, Lee B, Seo HY, Chung OH, Jung YS, Im E, et al. Redefining chronic inflammation in aging and age-related diseases: proposal of the SenoInflammation concept. Aging Dis. 2019;10(2):367–82.

21. Salam N, Rane S, Das R, Faulkner M, Gund R, Kandpal U, Lewis V, Mattoo H, Prabhu S, Ranganathan V, et al. T cell ageing: effects of age on development, survival & function. Indian J Med Res. 2013;138(5):595–608.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.